|
gptkbp:instanceOf
|
local anesthetic
antiarrhythmic agent
|
|
gptkbp:ATCCode
|
N01BB02
|
|
gptkbp:brand
|
gptkb:Lignocaine
gptkb:Xylocaine
|
|
gptkbp:CASNumber
|
137-58-6
|
|
gptkbp:category
|
amide-type local anesthetic
class 1b antiarrhythmic
|
|
gptkbp:chemicalFormula
|
C14H22N2O
|
|
gptkbp:combines
|
epinephrine
|
|
gptkbp:contraindication
|
hypersensitivity to amide-type anesthetics
|
|
gptkbp:discoveredBy
|
gptkb:Nils_Löfgren
|
|
gptkbp:discoveredIn
|
1943
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstSynthesized
|
gptkb:Sweden
|
|
gptkbp:halfLife
|
1.5–2 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lidocaine
|
|
gptkbp:IUPACName
|
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
|
|
gptkbp:KEGGID
|
gptkb:D08106
|
|
gptkbp:legalStatus
|
prescription only (US)
OTC (topical, some countries)
|
|
gptkbp:mechanismOfAction
|
blocks sodium channels
|
|
gptkbp:meltingPoint
|
68–69 °C
|
|
gptkbp:MeSH_ID
|
gptkb:D008008
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
234.34 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
60–80%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1539
gptkb:DB00281
3676
|
|
gptkbp:routeOfAdministration
|
injection
topical
transdermal
intravenous
|
|
gptkbp:sideEffect
|
dizziness
numbness
tingling
drowsiness
seizures (rare)
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
98PI200987
|
|
gptkbp:used_in_cardiac_arrhythmia
|
yes
|
|
gptkbp:used_in_dentistry
|
yes
|
|
gptkbp:used_in_minor_surgery
|
yes
|
|
gptkbp:used_in_nerve_block
|
yes
|
|
gptkbp:used_in_topical_pain_relief
|
yes
|
|
gptkbp:usedFor
|
local anesthesia
treatment of ventricular arrhythmias
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:Class_I_antiarrhythmic_drugs
|
|
gptkbp:bfsLayer
|
5
|